Copy Number Alterations in Myeloid Proliferative Neoplasms: Driver or Passenger of Leukaemic Transformation?
Infinite Science GmbH · 27.01.2026
DOI: 10.18416/scp.2026.2626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infinite Science GmbH, erschienen am 27.01.2026. Verfasst von Inken Dulige und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Post-Myeloproliferative neoplasms Acute Myeloid Leukaemia (post-MPN AML) is commonly characterised by TP53 mutations and a high burden of Copy Number Alterations (CNAs), yet the functional contribution of CNAs to leukaemic transformation remains unclear. In this study, single-cell RNA sequencing (scRNA-seq) data from 11 JAK2V617F TP53-mutant post-MPN AML patients were integrated with a JAK2V617F Trp53-loss mouse model to identify recurrent CNAs and their molecular consequences. We demonstrate that CNAs accumulate progressively across clonal stages and affect conserved pathways including PI3K/AKT/mTOR signalling, Myc targets, DNA repair, and apoptosis. Finally, synthetic lethal analysis reveal druggable vulnerabilities, highlighting potential therapeutic targets. Our results suggest that CNAs are not passengers but drivers of leukaemic transformation.
Schlagwörter
Zitieren
APA
Dulige, I., Lane, S., Fähnrich, A., Bywater, M. J., & Straube, J. (2026). Copy Number Alterations in Myeloid Proliferative Neoplasms: Driver or Passenger of Leukaemic Transformation?. Infinite Science GmbH. https://doi.org/10.18416/scp.2026.2626
Vancouver
Dulige I, Lane S, Fähnrich A, Bywater MJ, Straube J. Copy Number Alterations in Myeloid Proliferative Neoplasms: Driver or Passenger of Leukaemic Transformation?. Infinite Science GmbH. 2026. doi:10.18416/scp.2026.2626
BibTeX
@article{Dulige2026,
author = {Dulige, Inken and Lane, Steven and Fähnrich, Anke and Bywater, Megan J. and Straube, Jasmin},
title = {Copy Number Alterations in Myeloid Proliferative Neoplasms: Driver or Passenger of Leukaemic Transformation?},
journal = {Infinite Science GmbH},
year = {2026},
doi = {10.18416/scp.2026.2626}
}
EUVIMED